bexarotene has been researched along with Disease Exacerbation in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, H; Kubo, R; Morita, A; Muramatsu, S; Nishida, E; Tateishi, C; Tsuruta, D; Yonezawa, E | 1 |
| Einar French, L; Guertler, A; Helene Frommherz, L; Kaemmerer, T; Reinholz, M; Stadler, PC | 1 |
| Nathans, J; Williams, J; Wu, H | 1 |
| Acebo-Mariñas, E; Aperribay-Esparza, A; de Quintana-Sancho, A; Gardeazabal-García, J | 1 |
| Craig, FE; Grandinetti, LM; Ho, J; Jedrych, J; Johnson, WT; Leeman-Neill, RJ; Patel, P | 1 |
| Broussard, KC; Patrawala, SA; Wang, L; Zic, JA | 1 |
| Amitay-Laish, I; David, M; Hodak, E | 1 |
| Altiner, A; Berger, E; Chu, J; Latkowski, JA; Patel, R; Sanders, S | 1 |
| Assaf, C; Becker, JC; Dummer, R; Duvic, M; Grazia Bernengo, M; Lebbé, C; Marshood, M; Ortiz Romero, P; Poulalhon, N; Prince, HM; Squier, M; Tai, F; Williams, D | 1 |
| Baidas, S; Cohen, R; Demetri, GD; DeMichele, A; Dickler, M; Esteva, FJ; Glaspy, J; Hayes, DF; Hortobagyi, GN; Hutchins, L; Laufman, L; Osborne, CK; Tripathy, D; Winer, E; Yocum, RC | 1 |
| Jia, D; Lubet, RA; Wang, D; Wang, Y; Yao, R; You, M; Zhang, Z | 1 |
| Bohmeyer, J; Gellrich, S; Kremer, A; Luger, T; Muche, M; Nashan, D; Stadler, R; Sterry, W | 1 |
| Burg, G; Dummer, R; Hauschild, A; Skalsky, J; Weichenthal, M | 1 |
| Stadler, R | 1 |
| Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP | 1 |
| Alegre de Miquel, V; Pérez Ferriols, A; Roche Gamón, E; Vilata Corell, JJ | 1 |
| Dziewanowska, ZE; Gottfried, M; Jassem, J; Negro-Vilar, A; Negro-Vilar, R; Orlov, SV; Pereira, JR; Rahal, S; Ramlau, R; Schwarzenberger, P; Temperley, G; Zatloukal, P; Zhang, JK | 1 |
| Bischoff, ED; Heyman, RA; Lamph, WW | 1 |
| Duvic, M | 1 |
3 review(s) available for bexarotene and Disease Exacerbation
| Article | Year |
|---|---|
Mycosis fungoides stage IB progressing to cutaneous tumors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Black or African American; Disease Progression; Female; Humans; Interferon-alpha; Methotrexate; Mycosis Fungoides; Skin Neoplasms; Skin Pigmentation; Tetrahydronaphthalenes; Ultraviolet Therapy | 2011 |
Optimal combination with PUVA: rationale and clinical trial update.
Topics: Antineoplastic Agents; Bexarotene; Clinical Trials as Topic; Combined Modality Therapy; Diphtheria Toxin; Disease Progression; Doxorubicin; Humans; Immunologic Factors; Interferon-alpha; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Neoplasm Staging; Photopheresis; PUVA Therapy; Recombinant Fusion Proteins; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes | 2007 |
Current treatment of Cutaneous T-Cell Lymphoma.
Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Apoptosis; Bexarotene; Biopsy; Carmustine; Disease Progression; Drug Eruptions; Humans; Hypertriglyceridemia; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Neoplasm Staging; Prognosis; PUVA Therapy; Retinoids; Sezary Syndrome; Tetrahydronaphthalenes; Vitamin D | 2001 |
5 trial(s) available for bexarotene and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bexarotene; Disease Progression; Female; Heart Failure; Humans; Japan; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; PUVA Therapy; Sepsis; Severity of Illness Index; Skin Neoplasms; Treatment Outcome | 2020 |
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Disease Progression; Disease-Free Survival; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Mycosis Fungoides; Panobinostat; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2013 |
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Breast Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Tetrahydronaphthalenes; Thyroid Hormones; Toremifene; Treatment Outcome | 2003 |
Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma.
Topics: Adult; Aged; Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Disease Progression; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Tetrahydronaphthalenes; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2008 |
Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Survival Rate; Tetrahydronaphthalenes; Triglycerides; Vinblastine; Vinorelbine | 2008 |
11 other study(ies) available for bexarotene and Disease Exacerbation
| Article | Year |
|---|---|
Alitretinoin in the treatment of cutaneous T-cell lymphoma.
Topics: Adult; Aged; Alitretinoin; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Disease Progression; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Sezary Syndrome; Skin Neoplasms | 2021 |
Complete morphologies of basal forebrain cholinergic neurons in the mouse.
Topics: Alkaline Phosphatase; Alzheimer Disease; Animals; Axons; Basal Forebrain; Bexarotene; Cell Line; Cholinergic Neurons; Disease Models, Animal; Disease Progression; Hippocampus; Image Processing, Computer-Assisted; Mice; Mice, Knockout; Microscopy, Confocal; Tetrahydronaphthalenes | 2014 |
Cerebral involvement as the first extracutaneous manifestation of mycosis fungoides.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brain; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Fatal Outcome; Female; Humans; Lymphoma, Large-Cell, Anaplastic; Memory Disorders; Methotrexate; Middle Aged; Mycosis Fungoides; Nystagmus, Pathologic; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes | 2015 |
Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment.
Topics: Aged; Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Depsipeptides; Disease Progression; Drug Substitution; Fatal Outcome; Humans; Immunohistochemistry; Immunophenotyping; Lymphoma, T-Cell, Cutaneous; Male; Neoplasm Metastasis; Phenotype; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2016 |
Tumor stage mycosis fungoides: a single-center study on clinicopathologic features, treatments, and patient outcome.
Topics: Age Factors; Aged; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Cell Transformation, Neoplastic; Disease Progression; Female; Furocoumarins; Humans; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Prognosis; Radiotherapy; Retrospective Studies; Skin; Skin Neoplasms; Tertiary Care Centers; Tetrahydronaphthalenes; Ultraviolet Therapy | 2016 |
Systemic progression following complete cutaneous remission under bexarotene treatment for tumor-stage mycosis fungoides.
Topics: Bexarotene; Biopsy, Needle; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Mycosis Fungoides; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retreatment; Risk Assessment; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2009 |
Prevention of lung cancer progression by bexarotene in mouse models.
Topics: Adenocarcinoma; Adenoma; Animals; Anticarcinogenic Agents; Bexarotene; Carcinogens; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Disease Progression; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Tetrahydronaphthalenes; Urethane | 2006 |
Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Topics: Adult; Aged; Aminoquinolines; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Imiquimod; Immunosuppressive Agents; Interferons; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prednisone; PUVA Therapy; Remission Induction; Skin; Skin Neoplasms; Tacrolimus; Tetrahydronaphthalenes; Time Factors; Treatment Outcome; Vincristine | 2003 |
Bexarotene and systemic disease progression in CTCL?
Topics: Antineoplastic Agents; Bexarotene; Disease Progression; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Reproducibility of Results; Risk Factors; Sezary Syndrome; Tetrahydronaphthalenes | 2006 |
[Mycosis fungoid treated with oral bexarotene: study of 13 cases].
Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Disease Progression; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Remission Induction; Tetrahydronaphthalenes; Time Factors; Treatment Outcome | 2007 |
Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinogens; Disease Progression; Female; Mammary Neoplasms, Experimental; Methylnitrosourea; Rats; Rats, Sprague-Dawley; Tamoxifen; Tetrahydronaphthalenes; Treatment Failure; Treatment Outcome | 1999 |